<DOC>
	<DOCNO>NCT01093469</DOCNO>
	<brief_summary>The purpose study compare efficacy cost effectiveness Aquaphor Healing Ointment , Atopiclair EpiCeram monotherapy mild moderate AD . The investigator hypothesize statistical difference exist efficacy over-the-counter moisturizer , Aquaphor Healing Ointment , compare prescription device Atopiclair EpiCeram treat mild moderate AD . Therefore , Aquaphor cost-effective Atopiclair EpiCeram .</brief_summary>
	<brief_title>Comparing Efficacy Cost-Effectiveness Aquaphor Atopiclair EpiCeram Children With Mild Moderate Atopic Dermatitis</brief_title>
	<detailed_description>The primary objective compare efficacy Aquaphor Healing Ointment , Atopiclair Nonsteroidal Cream EpiCeram Skin Barrier Emulsion child mild moderate atopic dermatitis . The secondary objective compare cost-effectiveness product . A significant difference exist cost product ; therefore , hypothesis prove correct - Aquaphor efficacious expensive counterpart Atopiclair EpiCeram - could significant impact overall cost treating atopic dermatitis . This single center , investigator blind , randomize , prospective control study subject mild moderate atopic dermatitis . The study intend compare efficacy Aquaphor Healing Ointment , Atopiclair Nonsteroidal Cream EpiCeram Skin Barrier Emulsion use three time day treat mild moderate atopic dermatitis . All subject receive active study medication return study center efficacy safety assessment Days 7 21 . Approximately 50 subject enrol order obtain 39 complete subject randomize 1:1:1 ( 13 receive Aquaphor , 13 receive Atopiclair 13 receive EpiCeram ) accord standard randomization table . Efficacy measure Investigator 's Global Assessment , BSA involvement , Investigator Global Assessment Improvement , Eczema Area Severity Index 100-pt Visual Analog Score pruritis . Subjects complete Subject Global Assessment Improvement drug diary monitor compliance . Cost benefit analysis calculate cost dollar change outcome accord EASI , BSA VAS .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Decanoic acid</mesh_term>
	<mesh_term>Glycyrrhetinic Acid</mesh_term>
	<mesh_term>Petrolatum</mesh_term>
	<criteria>Male female mild moderate atopic dermatitis , 217 year age , agree participate provide write consent ( assent applicable ) Have investigator Global Assessment mild moderate atopic dermatitis ( IGA rating 23 Investigator Global Assessment ) Percentage overall body surface area involvement ( BSA ) must &gt; 1 % may include facial intertriginous skin . Use within 4 week baseline systemic antiinflammatory medication , may influence study outcome , systemic corticosteroid . Application use within 2 week baseline topical corticosteroid medication topical antiinflammatory medication , may influence study outcome . Presence concurrent medical condition , determine investigator potentially interfere study outcome patient assessment . Introduction prescription medication , topical systemic , atopic dermatitis participate int study ( oral antihistamine allow , long neither initiate discontinue course study ) Amount disease involvement would require &gt; 60gm cream 1 week period Subjects know allergy sensitivity Aquaphor Healing Ointment , Atopiclair EpiCeram component therein .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Atopic Dermatitis</keyword>
	<keyword>Wake Forest</keyword>
	<keyword>Dermatology</keyword>
	<keyword>Skin</keyword>
	<keyword>Over-the-counter</keyword>
	<keyword>Moisturizer</keyword>
	<keyword>Children</keyword>
</DOC>